MedTrace Logo

Prospective Study to Evaluate a Digital Regimen for Fibromyalgia Management: An Extension Study

NCT05433337 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-06-27

No results posted yet for this study

Summary

This study is designed as a 9-month extension of the original study (PROSPER-FM). The purpose of the extension study is to assess the long-term (up to 1 year) response to a digital therapy in the treatment of fibromyalgia.

Conditions

  • Fibromyalgia

Interventions

DEVICE

Digital ACT

Study participants will continue to receive Digital Acceptance and Commitment Therapy in addition to their standard care for fibromyalgia

Sponsors & Collaborators

  • Swing Therapeutics, Inc.

    lead OTHER

Principal Investigators

  • Brian Keefe, MD · Swing Therapeutics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
22 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-08
Primary Completion
2024-03-05
Completion
2024-03-05
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05433337 on ClinicalTrials.gov